MedPath

Impact of fat co-ingestion with protein on the post-prandial anabolic response in elderly me

Completed
Conditions
age-related muscle loss
sarcopenia
10037008
10028302
Registration Number
NL-OMON37092
Lead Sponsor
niversiteit Maastricht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
32
Inclusion Criteria

* Healthy males
* Age between 55 and 85
* BMI < 30 kg/m2

Exclusion Criteria

* Glucose intolerance
* Milk and/or fat intolerance
* Smoking
* Diagnosed GI tract diseases
* Arthritic conditions
* A history of neuromuscular problems
* Any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
* Use of anticoagulants
* Participation in exercise program
* Hypertention, high blood pressure above 140/90 mmHg

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study endpoint is muscle protein synthesis (MPS) rate. In order to<br /><br>determine the MPS, the following parameters will be measured in blood and<br /><br>muscle tissue:<br /><br>* Plasma phenylalanine concentration (expressed as *mol/L)<br /><br>* Plasma enrichment of L-[ ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine<br /><br>(expressed as mole percent excess, MPE)<br /><br>* Muscle protein bound enrichment of L-[ ring-2H5]-phenylalanine and<br /><br>L-[1-13C]-phenylalanine (expressed as MPE)<br /><br>* L-[ ring-2H5]phenylalanine and L-[1-13C]-phenylalanine enrichment of the<br /><br>muscle free amino acid pool (expressed as MPE)</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary endpoints include whole-body protein turnover, and protein digestion<br /><br>and absorption kinetics. The following parameters will be calculated:<br /><br>* Total rate of phenylalanine appearance and disappearance (= protein turnover)<br /><br>* Exogenous phenylalanine rate of appearance<br /><br>* Endogenous phenylalanine rate of appearance (=protein breakdown)<br /><br>* Plasma availability of phenylalanine</p><br>
© Copyright 2025. All Rights Reserved by MedPath